These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. Fogg C; Lustig S; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B J Virol; 2004 Oct; 78(19):10230-7. PubMed ID: 15367588 [TBL] [Abstract][Full Text] [Related]
4. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge. Pulford DJ; Gates A; Bridge SH; Robinson JH; Ulaeto D Vaccine; 2004 Sep; 22(25-26):3358-66. PubMed ID: 15308360 [TBL] [Abstract][Full Text] [Related]
5. Single-shot immunization with recombinant adenovirus encoding vaccinia virus glycoprotein A27L is protective against a virulent respiratory poxvirus infection. Rudraraju R; Ramsay AJ Vaccine; 2010 Jul; 28(31):4997-5004. PubMed ID: 20653083 [TBL] [Abstract][Full Text] [Related]
6. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Bell E; Shamim M; Whitbeck JC; Sfyroera G; Lambris JD; Isaacs SN Virology; 2004 Aug; 325(2):425-31. PubMed ID: 15246280 [TBL] [Abstract][Full Text] [Related]
7. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies. Golden JW; Josleyn MD; Hooper JW Vaccine; 2008 Jun; 26(27-28):3507-15. PubMed ID: 18485547 [TBL] [Abstract][Full Text] [Related]
8. Vaccination with a codon-optimized A27L-containing plasmid decreases virus replication and dissemination after vaccinia virus challenge. Martínez O; Bravo Cruz A; Santos S; Ramírez M; Miranda E; Shisler J; Otero M Vaccine; 2017 Oct; 35(44):6007-6014. PubMed ID: 28629922 [TBL] [Abstract][Full Text] [Related]
9. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host. Fang M; Cheng H; Dai Z; Bu Z; Sigal LJ Virology; 2006 Feb; 345(1):231-43. PubMed ID: 16256161 [TBL] [Abstract][Full Text] [Related]
10. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge. Clark KM; Johnson JB; Kock ND; Mizel SB; Parks GD Virology; 2011 Oct; 419(2):97-106. PubMed ID: 21885079 [TBL] [Abstract][Full Text] [Related]
11. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Hooper JW; Custer DM; Thompson E Virology; 2003 Feb; 306(1):181-95. PubMed ID: 12620810 [TBL] [Abstract][Full Text] [Related]
12. An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection. Morikawa S; Sakiyama T; Hasegawa H; Saijo M; Maeda A; Kurane I; Maeno G; Kimura J; Hirama C; Yoshida T; Asahi-Ozaki Y; Sata T; Kurata T; Kojima A J Virol; 2005 Sep; 79(18):11873-91. PubMed ID: 16140764 [TBL] [Abstract][Full Text] [Related]
13. Vaccinia virus strain LC16m8 defective in the B5R gene keeps strong protection comparable to its parental strain Lister in immunodeficient mice. Yokote H; Shinmura Y; Kanehara T; Maruno S; Kuranaga M; Matsui H; Hashizume S Vaccine; 2015 Nov; 33(45):6112-9. PubMed ID: 26241947 [TBL] [Abstract][Full Text] [Related]
14. Systemically administered DNA and fowlpox recombinants expressing four vaccinia virus genes although immunogenic do not protect mice against the highly pathogenic IHD-J vaccinia strain. Bissa M; Pacchioni SM; Zanotto C; De Giuli Morghen C; Illiano E; Granucci F; Zanoni I; Broggi A; Radaelli A Virus Res; 2013 Dec; 178(2):374-82. PubMed ID: 24050999 [TBL] [Abstract][Full Text] [Related]
15. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Xiao Y; Aldaz-Carroll L; Ortiz AM; Whitbeck JC; Alexander E; Lou H; Davis HL; Braciale TJ; Eisenberg RJ; Cohen GH; Isaacs SN Vaccine; 2007 Jan; 25(7):1214-24. PubMed ID: 17098336 [TBL] [Abstract][Full Text] [Related]
16. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917 [TBL] [Abstract][Full Text] [Related]
18. Effect of the deletion of genes encoding proteins of the extracellular virion form of vaccinia virus on vaccine immunogenicity and protective effectiveness in the mouse model. Meseda CA; Campbell J; Kumar A; Garcia AD; Merchlinsky M; Weir JP PLoS One; 2013; 8(6):e67984. PubMed ID: 23785523 [TBL] [Abstract][Full Text] [Related]
19. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. Davies DH; McCausland MM; Valdez C; Huynh D; Hernandez JE; Mu Y; Hirst S; Villarreal L; Felgner PL; Crotty S J Virol; 2005 Sep; 79(18):11724-33. PubMed ID: 16140750 [TBL] [Abstract][Full Text] [Related]
20. Smallpox subunit vaccine produced in Planta confers protection in mice. Golovkin M; Spitsin S; Andrianov V; Smirnov Y; Xiao Y; Pogrebnyak N; Markley K; Brodzik R; Gleba Y; Isaacs SN; Koprowski H Proc Natl Acad Sci U S A; 2007 Apr; 104(16):6864-9. PubMed ID: 17428917 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]